Brief: LAVA Doses First Patient In Phase 1 LAVA-1266 Study In Hematological Cancers
10/01/2025 13:57
Jan 10 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA DOSES FIRST PATIENT IN PHASE 1 LAVA-1266 STUDY IN
HEMATOLOGICAL CANCERS
* LAVA THERAPEUTICS NV: INITIAL PHASE 1 DATA READ-OUT
EXPECTED BY
YEAR-END 2025
Source text: urn:newsml:reuters.com:*:nGNXcbcydx
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM